Matteo Levisetti
Chief Tech/Sci/R&D Officer at CUE BIOPHARMA, INC.
Net worth: 15 045 $ as of 2024-05-30
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Daniel Passeri | M | 63 | 8 years | |
| Peter Kiener | M | 72 | 8 years | |
| Frank Morich | M | 69 | 6 years | |
| Kerri-Ann Millar | F | 54 | 7 years | |
| Fred Driscoll | M | 73 | 6 years | |
| Patrick Verheyen | M | 64 | 1 years | |
| Marie Campinell | F | - | - | |
| Colin Sandercock | M | 67 | 7 years | |
| Anish Suri | M | 50 | 6 years | |
| Pamela Garzone | M | 70 | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Frank Tufaro | M | 69 |
DNAtrix, Inc.
 DNAtrix, Inc. Electronic Equipment/InstrumentsElectronic Technology DNAtrix, Inc. operates as a biotech company which focuses on the development of oncolytic viruses for cancer. The firm’s offers DNX-2401 product which is an oncolytic virus designed specifically for treating Glioblastoma. It also works to expand its platform technology for treating other cancers, including ovarian, prostate and pancreatic cancer indications. The company was founded in 2005 by Francis Patrick McCormick, Alfred Yung, Charles Conrad, Cande Gomez-Manzano and Juan Fueyo and is headquartered in Houston, TX. | 9 years |
| Mark Gergen | M | 61 | 3 years | |
| Cameron Gray | M | 53 | 7 years | |
| Barry Simon | M | 59 | - | |
| Albert Hwang | M | - |
Pritzker School of Medicine
| 5 years |
| Ronald D. Seidel | M | - | 8 years | |
| Temre Johnson | M | - | 5 years | |
| Aaron Fletcher | M | 44 | 4 years | |
| Marcy Graham | F | 57 | - | |
| William Ringo | M | 78 | 2 years | |
| Tamar Howson | F | 75 | 3 years | |
| Bruce Carter | M | 80 | 8 years | |
| Chris LeMasters | M | - | 4 years | |
| Stephen Dilly | M | 64 |
DNAtrix, Inc.
DNAtrix, Inc. Electronic Equipment/InstrumentsElectronic Technology DNAtrix, Inc. operates as a biotech company which focuses on the development of oncolytic viruses for cancer. The firm’s offers DNX-2401 product which is an oncolytic virus designed specifically for treating Glioblastoma. It also works to expand its platform technology for treating other cancers, including ovarian, prostate and pancreatic cancer indications. The company was founded in 2005 by Francis Patrick McCormick, Alfred Yung, Charles Conrad, Cande Gomez-Manzano and Juan Fueyo and is headquartered in Houston, TX. | - |
| Claire S. Padgett | M | - | 1 years | |
| Joseph Luis Damasio | M | 49 | 1 years | |
| Kenneth J. Pienta | M | 64 | 6 years | |
| Jay Chen | M | - |
Pritzker School of Medicine
| 2 years |
| Thomas Fisher | M | - |
Pritzker School of Medicine
| 5 years |
| Melinda Ring | F | - |
Pritzker School of Medicine
| 4 years |
| Pat Nasshorn | F | 66 | 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 31 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Matteo Levisetti
- Personal Network
